Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced a Patient Savings Program for NURTEC™ ODT (rimegepant) that is now available for eligible commercially insured patients. The co-pay savings card can be obtained at the www.nurtec.com website after 12pm today. The U.S. Food and Drug Administration (FDA) approved NURTEC ODT for the acute treatment of migraine in adults on February 27, 2020. NURTEC ODT, which disperses almost instantly in a person’s mouth without the need for water, works by blocking the CGRP receptor, treating a root cause of migraine. NURTEC ODT is not indicated for the preventive treatment of migraine.